UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript

Operator: And I am showing no further questions. I would now like to turn the call back over to Liz Barrett for closing remarks.

Elizabeth Barrett: Thank you, and thanks, everybody, for your continued interest in UroGen. I think it’s been a tough market the last few weeks. But as everybody has seen that we’ve made significant progress. We continue to make significant progress both on JELMYTO and then importantly, on UGN-102. So appreciate, we have a lot of key catalysts coming up 6 months. So I appreciate your interest, and we’ll keep everybody posted. It’s a lot. Appreciate it. Operator, you can now disconnect.

Operator: That concludes today’s conference call. Thank you for participating. You may now disconnect.